News

April 10, 2024 - Nature

FOXO1 Supercharges CAR-T Cell Therapy

February 28, 2024 – Stanford Cancer Institute

CAR-T Cell Therapy in Solid Tumors

February 21, 2024 – Stanford News

A new RNA editing tool could enhance cancer treatment 

Text & Image

This is example text for the text & image component. To add or edit text here, double or right-click to bring up the editor.

November 27, 2023 – Society for Immunotherapy of Cancer

SITC Academy of Immuno-Oncology Honors Crystal Mackall as 2023 Fellow

November 27, 2023 – Society for Immunotherapy of Cancer

Alex Doan Receives 2023 SITC Abstract Travel Scholar Award

October 12, 2023 – The Mark Foundation for Cancer Research

Stanford Team Earns the 2023 MArk Foundation Endeavor Award

November 29, 2022 – Nature Reviews Drug Discovery

Transcription reprogramming to enhance CAR-T cell function

November 16, 2022 – Stanford Cancer Institute 

T cell effector programming is regulated by the Mediatro kinase module

October 25, 2022 – Frankfurter Stiftung für krebskranke Kinder

Johanna Theruvath awarded the 2022 Dr. Maresch-Klingelhöffer

October 18, 2022 – Stanford Cancer Institute

Crystal mackall is elected to the National Academy of Medicine

October 17, 2022 – Twitter

Louai Labanieh is featured in #FacesOfCell

September 13, 2022 – Stanford Office of Technology Licensing

Unlocking Cell Therapy in Pediatric Diseases: A Conversation with Crystal Mackall

August 30, 2022 – Sarcoma Foundation of America

SFA Honors Crystal L. Mackall with 2022 Nobility in Science Award 

July 27, 2022 – Parker Institute for Cancer Immunotherapy

Louai Labanieh is a 2022 Parker Scholar Awardee

April 12, 2022 – P.D. Soros Fellowships for New Americans

Quenton Bubb named Paul & Daisy Soros Fellow

March 22, 2022 - American Association for Cancer Research

Crystal Mackall named Fellow of the AACR Academy

Text & Image

This is example text for the text & image component. To add or edit text here, double or right-click to bring up the editor.

February 23, 2022 – Accelerating Cancer Immunotherapy Research

GD2-CAR-T cell therapy shows promis against deadly pediatric cancer in early clinical trail 

February 7, 2022 - Stanford Medicine Scope

From loss come hope: Pediatric brain tumor treatment shows promiss

December 12, 2021 -- Dr Lori Muffly Spotlights Disparities in Clinical Trial Enrollment, Patient Outcomes in Pediatric ALL

Lori Muffly, MD, associate professor of medicine, Blood & Marrow Transplantation, Stanford University, discusses findings of her study showing disparities in clinical trial enrollment and patient outcomes for at-risk pediatric minority populations with acute lymphoblastic leukemia (ALL).


September 9, 2021 - Stanford Medicine News

Crystal Mackall receives California Institute of Regenerative Medicine grant for CAR T clinical trial 

CAR-T cell therapy works for many types of blood cancers, but more than half of patients relapse. A Stanford study provides a clue as to why.


August 2, 2021 - Stanford Medicine News

Study predicts who may benefit from CAR-T cell therapy for blood cancers

CAR-T cell therapy works for many types of blood cancers, but more than half of patients relapse. A Stanford study provides a clue as to why.

 


June 14, 2021 - Cancer Cell 

CAR T cells need a pitstop to win the race

Prolonged TCR-driven stimulation can induce a dysfunctional T cell state, broadly described as T cell exhaustion, limiting the clinical potential of chimeric antigen receptor (CAR) T cells. Recent findings in Science indicate that early cessation of CAR T cell tonic signaling can prevent stabilization of exhaustion-associated epigenetic programs, enabling a prolonged anti-tumor response.

May 8, 2021 -- Crystal Mackall named Pediatric Oncology Award Recipient for Research in Immuno-Oncology

First delivered in 2002, the Pediatric Oncology Award recognizes someone who has demonstrated outstanding leadership or achievement in the field.


May 5, 2021 -- Evading exhaustion to improve CAR-T cell therapy

'Resting' exhausted cancer-fighting immune cells enhances their tumor-killing activity, which may help people with blood and solid cancers.


April 28, 2021 -- Team science award recognizes 8 pediatric cancer researchers at Stanford

Eight Stanford Medicine scientists are among a group of pediatric cancer researchers being honored with the 2021 Team Science Award from the American Association for Cancer Research.


April 8, 2021 -- Crystal Mackall receives AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research

Mackall will receive the AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research for her pioneering contributions to the fields of pediatric oncology, immunology, and immunotherapeutics, including her discovery of the role of IL-7 in T-cell homeostasis. The award also honors her significant efforts to advance the use of CAR T-cell therapies, and for consistent and ongoing translational research dedicated to establishing novel treatments for pediatric cancer patients.


April 8, 2021 -- St. Baldrick’s Foundation-Stand Up To Cancer Pediatric Cancer Dream Team receives AACR Team Science Award

The St. Baldrick’s Foundation-Stand Up To Cancer Pediatric Cancer Dream Team will receive the AACR Team Science Award for its significant contributions to the pediatric cancer research community, including more than 319 published manuscripts, 44 patent applications, a new clinical trials network, more than $118 million raised to support innovative research, and more than 1,113 children treated in early-phase clinical trials. Many of the children treated in these trials demonstrated durable complete responses.


April 30, 2020 -- New advances toward safely targeting immune cells to pediatric brain tumors

Stanford scientists have taken important steps toward figuring out how to use immune therapy for a group of severe pediatric brain tumors.


December 21, 2019 -- Synthetic Biology Just Keeps on Giving

Overexpression of c-Jun in CAR T cells induces resistance to exhaustion. This story started with an attempt to fix a flawed CAR, and led to the development of a human T cell exhaustion model that shines light into the basic biology of this process and suggests potential approaches to prevent it.


December 4, 2019 -- Stanford researchers program cancer-fighting cells to resist exhaustion, attack solid tumors in mice

CAR-T cells are remarkably effective against blood cancers, but their effect can be transient as the cells become exhausted. Stanford researchers found a way to keep the cells effective in mice with human tumors.


September 17, 2019 -- CureSearch Announces $1.2 Million Grant Supporting New CAR T-cell Therapy for DIPG

CureSearch announces its 2019 Catapult Award has been granted to immunologist Crystal Mackall, MD. This supports her research in CAR T-cell therapy. Co-funded by the Parker Institute for Cancer Immunotherapy (PICI), this $1.2 million award will fund a novel trial examining GD2 CAR T-cell therapy in diffuse intrinsic pontine glioma (DIPG), a highly aggressive brain tumor in children that has a 5-year survival rate of less than 1%.


July 17, 2017 -- Jeffrey and Marieke Rothschild gift establishes Stanford Center for Cancer Cell Therapy

Silicon Valley entrepreneur Jeffrey Rothschild and his wife, Marieke, have provided funding for a new venture at Stanford Medicine to test cancer cell therapies.